Evaluasi Keunggulan Tes Cepat Molekuler dengan Xpert MTB/ RIF Dibanding dengan Uji Mikroskopis dalam Mendiagnosis Tuberkulosis di Indonesia Tahun 2018
Abstract
Abstract
Tuberculosis (TB) remains a severe health issue worldwide which is one of the death leading causes, particularly in developing countries including Indonesia. The purpose of this study is to evaluate the superiority of the molecular diagnostic test with Xpert MTB/RIF compared to the microscopic test in 44 health facilities in Indonesia in 2018. The results revealed that the Xpert MTB/RIF test could detect 31,9% positive TB from 33,630 suspected cases. The Xpert MTB/RIF were also able to detect 16.7% positive samples from 5.491 samples which were previously negative tested by microscopic technique. The positive TB was dominated by the male in the age group of 15 to 54 years. Moreover, Xpert MTB/RIF test could examine the not-sputum samples of 0.16% (52 of 33,630 samples), which 9 samples of them were positive TB (17.3%). These positive TB samples were derived from gastric fluid (77.8%), pleural fluid (11.1%), and lymph node aspiration (11.1%), which majority were from children under 15 years old. This study concluded that the superiority of TCM test included its sensitivity to detect positive TB in resistant rifampicin cases, to identify the existence of MTB resistant to rifampicin drugs simultaneously and to detect the MTB with the non-sputum samples.
Keywords: evaluation, TB, Xpert MTB/RIF test
Abstrak
Tuberkulosis (TB) masih merupakan masalah kesehatan global yang serius dan penyebab utama kematian di seluruh dunia terutama di negara berkembang termasuk Indonesia. Tujuan dari penelitian ini adalah mengevaluasi keunggulan pemeriksaan diagnostik Tes Cepat Molekuler (TCM) Xpert MTB/RIF dibanding dengan pemeriksaan mikroskopis di 44 fasilitas kesehatan di Indonesia tahun 2018. Hasil pemeriksaan TCM dengan Xpert MTB/RIF dari 33.630 terduga TB terdapat TB positif sebesar 31,9%. Pemeriksaan mikroskopis dengan hasil negatif sebanyak 5.491 terduga TB yang juga diperiksa TCM dengan Xpert MTB/RIF terdapat hasil TB positif sebesar 16,7%. Hasil TB positif tersebut didominasi kelompok umur 15-54 tahun dan laki-laki. Pemeriksaan TCM ini juga mampu memeriksa spesimen bukan sputum sebesar 0,16% dan hasilnya 9 di antaranya adalah TB positif (17,3%). Spesimen TB positif ini berasal dari bilasan/ aspirasi cairan lambung 77,8% (7 dari 9 spesimen), cairan pleura 11,1% (1 dari 9 spesimen) dan aspirasi limfonodus 11,1% (1 dari 9 spesimen). Dilihat dari kelompok umur lebih dari separuh spesimen bukan sputum ini berasal dari anak <15 tahun. Penelitian ini menyimpulkan bahwa TCM dengan Xpert MTB/RIF lebih unggul daripada pemeriksaan mikroskopis karena sensitivitasnya pada rifampisin sensitif maupun resisten, mampu mengidentifikasi keberadaan MTB yang resisten obat rifampisin secara bersamaan serta sampel bukan-sputum.
Kata kunci: Evaluasi, TB, Tes Cepat Molekuler dengan Xpert MTB/RIF
References
WHO. Global Tuberculosis Report 2019. WHO. 2019.
National Institute of Health Research and Development Ministry of Health. Tuberculosis Inventory Study Results, Indonesia 2017. 2017.
WHO. Global Tuberculosis Report. 2018.
Pfyffer GE, Wittwer F. Incubation time of mycobacterial cultures: How long is long enough to issue a final negative report to the clinician? J Clin Microbiol. 2012;50(12):4188– 9.
Moure R, Mun L, Torres M, Santin M, Martín R, Alcaide F. Rapid Detection of Mycobacterium tuberculosis Complex and Rifampin Resistance in Smear-Negative Clinical Samples by Use of an Integrated Real-Time PCR Method. J Clin Microbiol. 2011;49(3):1137–9.
WHO. Xpert MTB / RIF implementation. WHO; 2014. 1–52 p.
Millen SJ, Uys PW, Hargrove J, van Helden PD, Williams BG. The effect of diagnostic delays on the drop-out rate and the total delay to diagnosis of tuberculosis. PLoS One. 2008;3(4).
Kr, Steingart, Schiller I, Dj H, Pai M, Cc B, et al. Xpert ® MTB / RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review). Cochrane Database Syst Rev. 2015;(1):1–167.
Steingart KR, Ramsay A, Pai M. Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. Expert Rev Anti Infect Ther. 2007;5(3):327–31.
Kemenkes RI. (2016). Peraturan Menteri Kesehatan Republik Indonesia No.67 Tahun 2016 Tentang Penanggulangan Tuberkulosis
Dina Bisara, dkk., Laporan “Studi evaluasi deteksi kasus TB dengan alat TCM di Indonesia tahun 2018”.2018. Jakarta.
Kemenkes RI, Petunjuk Teknis Pemeriksaan TB Menggunakan Tes Cepat Molekuler. 2017. Jakarta.
Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005– 15.
Erizka Rivani, Tia Sabrina VP. Perbandingan uji diagnostik GeneXpert MTB / RIF untuk mendeteksi resistensi rifampicin Mycobacterium tuberculosis pada pasien Tb paru di RSUP dr. Moh. Hoesin Palembang. JKK. 2019;6(1):23–8.
Tadesse M, Aragaw D, Rigouts L, Abebe G. Increased detection of smear-negative pulmonary tuberculosis by GeneXpert MTB/ RIF® assay after bleach concentration. Int J Mycobacteriology [Internet]. 2016;5(2):211–8. Available from: http://dx.doi.org/10.1016/j.ijmyco.2016.03.005
M. H. Phyu, K. W. Y. Kyaw, Z. Myint, A. Thida, S. Satyanarayana STA. Sputum smear-positive, Xpert® MTB/RIF-negative results: magnitude and treatment outcomes of patients in Myanmar. Public Heal Action. 2018;8(4):181–186.
WHO. Xpert MTB / RIF implementation manual. World Heal Organ. 2014;1:52.
Fanosie A, Gelaw B, Tessema B, Tesfay W, Admasu A, Yitayew G. Mycobacterium Tuberculosis complex and HIV co-infection among Extrapulmonary Tuberculosis suspected cases at the University of Gondar hospital, northwestern Ethiopia. PLoS One [Internet]. 2016;11(3):1–15. Available from:http://dx.doi.org/10.1371journal.pone.0150646
Hillemann D, Rüsch-Gerdes S, Boehme C, Richter E. Rapid molecular detection of extrapulmonary tuberculosis by the automated genexpert MTB/RIF system. J Clin Microbiol. 2011;49(4):1202–5.
Walters E, Zalm MM Van Der, Palmer M, Schaaf HS, Friedrich SO, Whitelaw A, et al. Xpert MTB/RIF on Stool is useful for rapid diagbosis of TB in children with severe pulmonary disease. Pediatr Infect Dis J. 2018;36(9):837–43.
Lu Y, Zhu Y, Shen N, Tian L, Sun Z. Evaluating the diagnostic accuracy of the Xpert MTB/ RIF assay on bronchoalveolar lavage fluid: A retrospective study. Int J Infect Dis [Internet]. 2018;71:14–9. Available from:.https://doi.org/10.1016/j.ijid.2018.01.030
Metaferia Y, Seid A, Fenta GM, Gebretsadik D. Assessment of Extrapulmonary Tuberculosis Using Gene Xpert MTB/RIF Assay and Fluorescent Microscopy and Its Risk Factors at Dessie Referral Hospital, Northeast Ethiopia. Biomed Res Int. 2018;2018.
Alvarez-Uria G, Azcona JM, Midde M, Naik PK, Reddy S, Reddy R. Rapid Diagnosis of Pulmonary and Extrapulmonary Tuberculosis in HIV-Infected Patients. Comparison of LED Fluorescent Microscopy and the GeneXpert MTB/RIF Assay in a District Hospital in India. Tuberc Res Treat. 2012;2012:1–4.
Newton S, Brent A, Anderson S, Whittaker E, Kampmann B. Paediatric Tuberculosis (UKPMC Funders Group). Lancet Infect Dis. 2008;8(8):498–510.
Raizada N, Khaparde SD, Rao R, Kalra A, Sarin S, Salhotra VS, et al. Upfront Xpert MTB/RIF testing on various specimen types for presumptive infant TB cases for early and appropriate treatment initiation. PLoS One [Internet]. 2018;13(8):1–14. Available from: http://dx.doi.org/10.1371/journal.pone.0202085
Betty Agustina, Cissy Kartasasmita DH. Comparison of GeneXpert MTB to Mycobacterium tuberculosis culture in children with tuberculosis. Paediatr Indones. 2019;59(3):113–8.
Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet [Internet]. 2011;377(9776):1495–505. Available from: http://dx.doi.org/10.1016/S0140-6736(11)60438-8
WHO. WORLD HEALTH STATISTICS SDG s. World Heal Stat 2016 [Internet]. 2016;130. Available from: http://www.who.int/gho/publications/world_health_statistics/en/.
Copyright (c) 2020 Buletin Penelitian Kesehatan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Publishing your paper with Buletin Penelitian Kesehatan means that the author or authors transfer the copyright to Buletin Penelitian Kesehatan. Buletin Penelitian Kesehatan granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially.
Buletin Penelitian Kesehatan journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.
Buletin Penelitian Kesehatan journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
- BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
